Lisa Zambrano
Nurse Practitioner · Dallas, TXNPI 1073559886
Payments from drug & device makers
Across 287 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Medtronic$746
- Sumitomo Pharma America, Inc.$695
- Axonics, Inc.$516
- AbbVie$405
- Johnson & Johnson$399
- plus $4K from 32 others
What the payments were for
- Travel & lodging$270%
- Food & beverage$7,06897%
- Education$2003%
- Entertainment$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 43 | $1,006 |
| Medtronic | 16 | $746 |
| Sumitomo Pharma America, Inc. | 27 | $695 |
| Axonics, Inc. | 16 | $516 |
| AbbVie | 14 | $405 |
| Johnson & Johnson | 7 | $399 |
| Dendreon Pharmaceuticals LLC | 11 | $350 |
| Tolmar, Inc. | 32 | $347 |
| Antares Pharma, Inc. | 12 | $261 |
| Merck | 8 | $243 |
| Urovant Sciences Inc | 7 | $225 |
| Bayer | 10 | $223 |
| Verity Pharmaceuticals Inc. | 20 | $208 |
| Coloplast | 7 | $206 |
| Endo Pharmaceuticals Inc. | 8 | $171 |
| Halozyme Inc | 1 | $139 |
| Endo USA, Inc. | 6 | $132 |
| Ferring Pharmaceuticals Inc. | 5 | $128 |
| Pfizer | 5 | $125 |
| Photocure Inc | 1 | $121 |
| Acerus Pharmaceuticals Corporation | 6 | $96 |
| Boston Scientific | 3 | $88 |
| Urogen Pharma, Inc. | 2 | $64 |
| 180 Medical, Inc. | 1 | $51 |
| Procept Biorobotics Corporation | 3 | $47 |
| Innovation Technologies Inc | 1 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| AstraZeneca | 2 | $38 |
| Immunitybio, Inc. | 1 | $29 |
| Mission Pharmacal Company | 2 | $25 |
| Teleflex LLC | 1 | $25 |
| Millicent US Inc | 1 | $19 |
| Myovant Sciences Inc. | 1 | $18 |
| Provepharm Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Calyxo, Inc. | 1 | $16 |
| Valencia Technologies Corporation | 1 | $15 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,313 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 240 | $142,519 |
| GemtesaVibegron | 113 | $82,675 |
| Mirabegron ErMirabegron | 33 | $15,466 |
| NitrofurantoinNitrofurantoin Macrocrystal | 306 | $10,596 |
| Trospium Chloride ErTrospium Chloride | 49 | $9,228 |
| Trospium Chloride | 140 | $6,780 |
| Methenamine Hippurate | 83 | $5,700 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 293 | $4,494 |
| Fosfomycin Tromethamine | 26 | $3,851 |
| Estradiol | 54 | $2,763 |
| Solifenacin Succinate | 105 | $2,280 |
| Oxybutynin Chloride ErOxybutynin Chloride | 87 | $2,088 |
| Cefdinir | 105 | $1,670 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 14 | $1,532 |
| Silodosin | 13 | $912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,006 | $142,519240 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $695 | $82,675113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Dallas
- Samantha OnealDallas$133K
- Tam TranDallas$37K
- Tobin SpeightDallas$35K
- Rachel TiuDallas$19K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.